Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,612.00
Bid: 1,611.50
Ask: 1,612.50
Change: -4.50 (-0.28%)
Spread: 1.00 (0.062%)
Open: 1,619.50
High: 1,620.50
Low: 1,610.50
Prev. Close: 1,616.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 13th Oct 2014 09:32

Amino Technologies: Northland Capital upgrades to buy with a target price of 100p.Anglo American: Canaccord Genuity initiates with a target price of 1720p and a buy recommendation. Credit Suisse upgrades to outperform with a target price of 1800p.Associated British Foods: Societe Generale upgrades to buy with a target price of 2950p.AstraZeneca: Jefferies raises target price from 4500p to 5000p upgrading to buy.Betfair Group: Numis reduces target price from 1250p to 940p downgrading to reduce.Bodycote: Investec cuts target price from 775p to 750p and stays with its buy recommendation.Brammer: Investec cuts target price from 435p to 400p, while keeping a buy recommendation.Brown (N) Group: N+1 Singer reduces target price from 585p to 390p, while staying with its buy recommendation. Jefferies cuts target price from 540p to 406p and reiterates a buy recommendation.BTG: Investec raises target price from 728p to 832p staying with its buy recommendation.bwin.party: Numis cuts target price from 200p to 180p and keeps a buy recommendation.Coca-Cola HBC: Credit Suisse reduces target price from 1500p to 1400p, while maintaining its neutral rating.Dialight: Investec reduces target price from 910p to 850p downgrading to sell.Domino Printing: Investec cuts target price from 650p to 615p keeping an add rating.Eagle Eye: Panmure Gordon initiates with a target price of 229p and a buy recommendation.Fenner: Investec cuts target price from 320p to 270p and retains a sell recommendation.Ferrexpo: Cantor Fitzgerald reduces target price from 250p to 120p maintaining a buy recommendation.GKN: Investec cuts target price from 380p to 330p, while upgrading from add to buy.GlaxoSmithKline: Jefferies ups target price from 1385p to 1400p and retains a hold recommendation.Glencore: Canaccord Genuity initiates with a target price of 400p and a buy recommendation.Halma: Investec lowers target price from 635p to 630p and maintains a buy recommendation.Hellermann Tyton: Investec lowers target price from 305p to 300p and retains a hold recommendation.IMI: Investec reduces target price from 1560p to 1425p and keeps a buy recommendation.IMImobile: WH Ireland ups target price from 175p to 187p and retains a buy recommendation.Jupiter Fund Management: JP Morgan cuts target price from 465p to 400p staying with an overweight rating. Espirito Santo cuts target price from 489p to 469p leaving its buy recommendation unaltered.Ladbrokers: Numis reduces target price from 150p to 100p downgrading to reduce.Laird: Investec lowers target price from 260p to 250p leaving its sell recommendation unchanged.Melrose: Investec shifts target price from 332p to 335p and keeps a buy recommendation.Molins: Panmure Gordon reduces target price from 250p to 165p and stays with its buy recommendation.Morgan Advanced Materials: Investec lowers target price from 345p to 335p reiterating its buy recommendation.Oxford Instruments: Investec reduces target price from 1520p to 1405p and reiterates a buy recommendation.Paragon Group: JP Morgan ups target price from 396p to 420p and leaves its overweight rating unchanged.Playtech: Numis cuts target price from 700p to 665p and reiterates a hold recommendation.Renishaw: Investec reduces target price from 1900p to 1775p keeping a buy recommendation.Rotork: Investec reduces target price from 2840p to 2610p retaining its add rating.Smith (DS): Investec cuts target price from 380p to 350p and stays with its buy recommendation.Smith & Nephew: Investec reduces target price from 1100p to 1023p and downgrades from add to hold.Smith (WH): Canaccord Genuity initiates with a target price of 1225p and a buy recommendation.Spectris: Investec reduces target price from 2580p to 2380p and maintains a buy recommendation.Spirax-Sarco: Investec reduces target price from 2920p to 2810p and stays with its add rating.TSB: Investec shifts target price from 290p to 295p upgrading from hold to buy.Vedanta Resources: Canaccord Genuity initiates with a target price of 1020p and a hold recommendation. JP Morgan lowers target price from 1140p to 1130p and retains its neutral rating.Vesuvius: Investec cuts target price from 485p to 450p and reiterates an add rating.Vitec Group: Investec cuts target price from 790p to 740p maintaining a buy recommendation.Weir Group: Investec raises target price from 2400p to 2525p, but still recommends selling.William Hill: Numis reduces target price from 500p to 400p downgrading to add.888 Holdings: Numis cuts target price from 220p to 175p and keeps a buy recommendation.32Red: Numis lowers target price from 100p to 80p, while retaining its buy recommendation.
More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.